---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-026343"
form_type: "8-K"
ticker: "IDXG"
cik: "0001054102"
company_name: "INTERPACE BIOSCIENCES, INC."
filed_at: "2023-08-02T23:59:59+00:00"
generated_at: "2026-06-12T11:12:04.888109+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Interpace Biosciences appoints Christopher McCarthy as CFO effective July 24, 2023

## Summary
- McCarthy previously served as Principal Financial Officer since April 2023; base salary set at $220,000.
- Eligible for annual bonus target up to 40% of base salary; received RSU grant of 25,000 shares (12,500 vested immediately, remainder in 6 months).
- Additional 25,000 RSUs to be granted on July 27, 2024, fully vested on grant date.
- Severance of 6 months base salary plus COBRA premiums for 6 months upon termination without cause or for good reason, subject to release.
- Employment is at-will; no family relationships or related party transactions disclosed.

## SEC filing metadata
- accession: 0001493152-23-026343
- form_type: 8-K
- ticker: IDXG
- cik: 0001054102
- company_name: INTERPACE BIOSCIENCES, INC.
- filed_at: 2023-08-02T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1054102/000149315223026343/0001493152-23-026343-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1054102/000149315223026343/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-026343
- JSON: https://secwatch.observer/filing/0001493152-23-026343.json
- Plain text: https://secwatch.observer/filing/0001493152-23-026343.txt

## Key facts
- Executive change
  Christopher McCarthy was appointed as Chief Financial Officer at INTERPACE BIOSCIENCES, INC..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: On July 24, 2023, the Board of Directors (the “ Board ”) of Interpace Biosciences, Inc. (the “ Company ”) appointed Christopher McCarthy, age 32, as Chief Financial Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1054102/000149315223026343/0001493152-23-026343-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.